GlassScriptPhysician profile
Shawn Keller
NPI 1063048940
$7,929.50
in general payments reported to CMS, 2019-2025
34 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,232 · 2022: $1,501 · 2023: $2,027 · 2024: $1,460 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,195.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,050.67 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $987.99 | 2021-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $800.46 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Gilead Sciences, INC. | $640.34 | 2021-2025 | Biktarvy, Epclusa, Yeztugo |
| Alkermes, INC. | $432.08 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $414.04 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $403.79 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $291.25 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Merck Sharp & Dohme LLC | $252.76 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Glaxosmithkline, LLC. | $240.46 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $229.35 | 2022-2025 | Spravato |
| Novo Nordisk INC | $215.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.87 | 2021-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.36 | 2021 | |
| Corium, LLC | $156.45 | 2022-2025 | Azstarys |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $154.97 | 2021-2023 | Repatha |
| Axsome Therapeutics, INC. | $140.53 | 2024-2025 | Auvelity, Symbravo |
| Sunovion Pharmaceuticals INC. | $139.05 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $116.96 | 2024 | Opsumit, Uptravi |
| Indivior INC. | $113.39 | 2021-2024 | Perseris |
| Viiv Healthcare Company | $102.08 | 2022-2025 | Apretude |
| Exact Sciences Corporation | $97.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $88.49 | 2021-2025 | Takhzyro, Trintellix |
| Pharming Healthcare, INC. | $80.71 | 2025 | Ruconest |
| Biocryst US Sales Co., LLC | $79.83 | 2022-2025 | Orladeyo |
| Lundbeck LLC | $74.56 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lilly USA, LLC | $73.84 | 2021-2025 | Mounjaro |
| Organon LLC | $54.27 | 2023-2024 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $44.80 | 2022-2024 | |
| Dexcom, INC. | $42.25 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $20.16 | 2024 | Affirm Prone Biopsy System |
| Abbott Laboratories | $18.23 | 2025 | Freestyle Libre |
| Ardelyx, INC. | $15.54 | 2025 | Ibsrela |
| Sun Pharmaceutical Industries INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.